Lipid-lowering therapy and LDL target attainment in type 2 diabetes: trends from the Italian Associations of Medical Diabetologists database
While LDL-c management in Italian patients with T2DM has improved, significant gaps remain, particularly for very high-risk individuals. Expanding the use of advanced therapies like PCSK9 inhibitors and adhering more closely to guideline-based recommendations are critical to improve cardiovascular risk in this population.
Authors
- Marco Muselli (ORCID: https://orcid.org/0000-0002-9999-2331)
- Rita Zilich (ORCID: https://orcid.org/0000-0002-4590-9395)
- Fabio Baccetti (ORCID: https://orcid.org/0000-0002-0008-1336)
- Davide Masi (ORCID: https://orcid.org/0000-0003-0820-633X)
- Damiano Verda (ORCID: https://orcid.org/0000-0001-9912-3454)
- Pierpaolo Falcetta (ORCID: https://orcid.org/0000-0002-3182-0453)
- Enrica Salomone
- Walter Baronti (ORCID: https://orcid.org/0000-0002-4532-3028)
- Alessandro Ozzello (ORCID: https://orcid.org/0000-0002-0876-5134)
- Nicoletta Musacchio (ORCID: https://orcid.org/0000-0001-9530-2869)
- Paola Ponzani (ORCID: https://orcid.org/0000-0002-0961-0302)
- Antonio Rossi (ORCID: https://orcid.org/0000-0002-8660-2146)
- Lelio Morviducci
- Riccardo Candido (ORCID: https://orcid.org/0000-0003-2385-9160)
- Maria Vezenkova
Institutions
- University of Pisa (IT)
- University of Milan (IT)
- ASL Roma (IT)
- Toscana Biomarkers (Italy) (IT)
- Istituto Clinico Sant'Ambrogio (IT)
- Ospedale Misericordia - Grosseto (IT)
- Associazione Medici Diabetologi (IT)
- Sapienza University of Rome (IT)
Publication Details
- Journal
- Cardiovascular Diabetology
- Published
- 2025-02-28
- DOI
- https://doi.org/10.1186/s12933-025-02648-1
- Citations
- 4
- Primary Topic
- Lipoproteins and Cardiovascular Health
- Type
- article
- Field-Weighted Citation Impact
- 8.03
Funders
- Sanofi